Takeda Ansioli (injection of Vibutuximmonob.

Read: Opens a new chapter in CD30-positive lymphoma treatment. On August 6,
, Takeda China announced the launch of its drug Amsley ® (injection with Vibutuxiaxmono), which offers new treatment options for adult patients with CD30-positive recurrent or refractive systemic interstiturate cell lymphoma (sALCL) and classic Hodgkin lymphoma (cHL).
as the world's first and currently the only CD30 target antibody conjugate drug, Amsley ® (injection of vitutoxi monosar) has been approved in more than 70 countries and regions for lymphoma treatment, clinical use experience, real-world evidence-based, long-established efficacy.
data show that the ® of amsley (injection of vibutuxib monosar) can significantly prolong the long-term survival of patients with recurrent or refractable lymphoma: the median total survival (OS) of patients with recurrent or refractable cHL increased from 10.5 months to 27.6 months to 40.5 months, and the five-year survival rate of patients with relapsed or refracted sALCL can be increased to 60%.
lymphoma is one of the top 10 most deadly malignant tumors in China, with about 93,000 people diagnosed with lymphoma each year and more than 50,000 people dying from the cancer.
, the current domestic treatment for relapsed or refracted systemic intercellular cell lymphoma and classic Hodgkin lymphoma is limited, the survival of patients is not optimistic.
data show that about 40% to 64% of patients with systemic interstitulated large cell lymphoma still have relapse or progression after first-line treatment, and the prognosis of chemotherapy after recurrence is poor.
taking relapsed or refractivated systemic interstitial large cell lymphoma as an example, according to a retrospective analysis, after chemotherapy in patients with relapsed or incurable sALCL, the median PFS (no progression survival) was only 1.8 months, while the median OS (total survival) was only 3.0 months;
.